First Manhattan CO Biomarin Pharmaceutical Inc Transaction History

First Manhattan CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $4,483 - $5,441	60 New	60 $4,000
Q2 2019 Aug 16, 2019	SELL	$80.35 - $93.9 $48,210 - $56,340	-600 Closed	0 $0
Q1 2018 Apr 20, 2018	SELL	$77.67 - $92.63 $48,543 - $57,893	-625 Reduced 51.02%	600 $48,000
Q4 2017 Jan 22, 2018	BUY	$80.76 - $95.13 $50,475 - $59,456	625 Added 104.17%	1,225 $109,000
Q3 2017 Oct 25, 2017	BUY	$80.6 - $94.95 $48,360 - $56,970	600	600 $55,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.